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Abstract 
Background: This short report arose from a follow-up study of children previously diagnosed with human immu-
nodeficiency virus (HIV) encephalopathy and spastic diplegia and is among the first to describe that increased lower 
limb muscle tone in children with a confirmed HIV encephalopathy diagnosis may resolve over time in some cases.
Results: Of 19 children previously diagnosed with HIV encephalopathy and increased lower limb muscle tone, some 
were found to have resolved muscle tone abnormalities during a follow-up physical examination [resolved group, 
n = 13, median age 9 years 7 months (interquartile range 7 years 3 months–10 years 9 months)] whereas others 
continued to show increased lower limb muscle tone at follow-up [unresolved group, n = 6 median age 8 years 
6 months (interquartile range 7 years 9 months–9 years 7 months)]. A review of clinical records showed no significant 
differences in age or follow-up time between the resolved and unresolved groups. However, the unresolved group 
appeared to have severe disease at an earlier age than the resolved group, based on the age at antiretroviral treat-
ment initiation [median age at start of treatment 2 years 3 months (interquartile range 7 months–5 years 3 months) 
vs. 8 months (interquartile range 6–12 months), p = 0.08] and had more severe neurological signs at the initial 
assessment.
Conclusions: It is anticipated that this information may be of immediate value to those involved in the treatment 
of children with HIV encephalopathy and increased lower limb muscle tone whilst awaiting the outcome of future 
controlled clinical trials.
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Background
It is estimated that at least 210,000 children in South 
Africa are infected with human immunodeficiency 
virus (HIV) with vertical transmission identified as the 
most common mode of pediatric HIV infection [1]. 
HIV may penetrate the central nervous system (CNS) 
early in infection and children infected with HIV dur-
ing the perinatal period may subsequently develop HIV 
encephalopathy (HIVE) [2, 3]. For example, it was 
recently reported that of 145 children seen at an HIV 
Neurology clinic at the Red Cross War Memorial Chil-
dren’s Hospital in Cape Town between 2008 and 2012, 87 
children (60 %) could be regarded as having an isolated 
diagnosis of HIVE [4]. Furthermore, 55 (63 %) of the chil-
dren were reported as having spastic diplegia, including 
pathological gait patterns, as part of the HIVE diagnosis 
[4].
Little is known about the natural history of spastic 
diplegia in children with HIVE and with this in mind, a 
study investigating this topic was planned and approved 
by the University of Cape Town Human Research 
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Ethics Committee (HREC 447/2012). Participants for 
the study were recruited from the afore-mentioned HIV 
Neurology clinic, which has ethical approval to collect 
information on a password protected database (HREC 
126/201). It was anticipated that the original neurologi-
cal findings would be confirmed during the screening of 
potential participants. However, more than two-third of 
the children screened no longer showed any evidence of 
spastic diplegia or increased muscle tone in the lower 
limbs.
Improvement in lower limb tone abnormalities in chil-
dren with HIVE has been previously alluded to by Chiri-
boga et al. [5]. However, these observations fell beyond 
the main scope of the study and it remains unclear why 
increased muscle tone in the lower limbs of children 
diagnosed with HIVE appears to resolve in some chil-
dren but not in others. In a similar way, this topic was 
not the aim of our planned research study. Nevertheless, 
we felt it important to report our clinical observations 
and offer preliminary insights into the possible role of 
(1) the current age of the children and follow-up time; 
(2) the severity of the initial neurological findings and; 
(3) age at the start of antiretroviral therapy (ART) on 
the subsequent resolution of increased lower limb mus-
cle tone. It is anticipated that this information may be 
of immediate value to those involved in the treatment 
of children with HIVE and increased lower limb muscle 




The current clinical observations occurred whilst screen-
ing possible participants for a study on the natural his-
tory of HIVE and spastic diplegia. Children potentially 
eligible for the study were identified from a database, 
which was compiled by two pediatric neurology special-
ists (KD and KW) at the HIV Neurology clinic of Red 
Cross War Memorial Children’s Hospital between 2008 
and 2014. The database included each child’s medical his-
tory, the findings of a physical examination (PE 1) and the 
neurologist’s diagnostic conclusions.
Parents or caregivers were invited to bring their child 
to the hospital for counselling regarding informed con-
sent and screening if the child appeared to meet the 
criteria for the study. All children had HIVE, diagnosed 
according to Centers for Disease Control (CDC) crite-
ria [7]; were recorded as having spastic diplegia and/or 
increased muscle tone in the lower limbs; were ambu-
lant; had no history of prematurity; no neurosurgical or 
orthopedic interventions; no botulinum toxin injections 
within the last 6 months; and currently were between 5 
and 12 years of age.
Outcome measures
During the screening, a highly experienced physiothera-
pist (NL) conducted a follow-up physical examination of 
the child’s lower limbs (PE 2). The assessment included 
testing muscle tone in the child’s hip flexor, rectus femo-
ris, hamstring, adductor and plantar flexor muscles and 
visual inspection of the child’s walking and running gait 
pattern for abnormalities related to muscle spasticity. In 
addition, clinical records were used to gather informa-
tion regarding each child’s (1) age and follow-up time; (2) 
severity of the initial neurological findings; and (3) age 
at the start of ART. Most recent CD4 and viral load (VL) 
results, dating from within approximately 1 year of PE 2, 
were also recorded along with the current ART regimen. 
The CNS penetration-effectiveness (CPE) score for each 
antiretroviral drug was taken from the revised CPE rank-
ing of Letendre et  al. [6] with higher scores indicating 
better effectiveness. Total CPE score for the regimen was 
taken as the sum of the CPE scores for each component.
Data analysis
Children were divided into those who had normal lower 
limb muscle tone at PE 2 (resolved group) and those who 
continued to show increased lower limb muscle tone at 
PE 2 (unresolved group). All data was analyzed using 
Graphpad Prism (Version 6, Graphpad Software Inc, 
California, USA) and presented as the median value and 
inter-quartile range (IQR). A two-tailed Mann–Whit-
ney U test was used to compare outcome measures in 




Nineteen children identified from the database as poten-
tially eligible for the study attended a screening session. 
Thirteen of the 19 children previously recorded with 
spastic diplegia or increased muscle tone in the lower 
limbs no longer showed any evidence of these signs 
(resolved group—6 boys, 7 girls) whereas the remaining 
six children continued to show increased muscle tone in 
the lower limbs (unresolved group—5 boys, 1 girl).
Age and follow‑up time
Table  1 provides an overview of age and follow-up 
time for the resolved and unresolved groups, respec-
tively. There were no significant differences between the 
resolved and unresolved groups with respect to age at PE 
1, PE 2 or follow-up time between PE 1 and PE 2.
Severity of the initial neurological findings
While all 19 children had shown increased lower limb 
muscle tone at PE 1, this finding had been recorded as 
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“increased lower limb muscle tone” in some cases and 
“spastic diplegia” in other cases, indicating variation in 
the relative severity of the initial neurological findings. 
All 13 children in the resolved group were described 
as having “increased muscle tone” at PE 1, with none 
described as having “spastic diplegia”. In contrast, five of 
the six children in the unresolved group were described 
as having “spastic diplegia” at PE 1, with the remaining 
child described as having “increased muscle tone”.
ART initiation, recent blood test results and current ART 
regimen
There were no significant differences in the age at ART 
initiation, time on ART prior to PE 1 and time on ART 
prior to PE 2 (Fig. 1a–c). Most recent blood test results 
showed no immune suppression (n  =  10) or moderate 
immune suppression (n =  2) within the resolved group 
according to CDC immunologic classification [7] with 
one result unavailable. All children in the unresolved 
group had no immune suppression. Most children in the 
resolved group had undetectable VL’s (n = 11) although 
two children had VL’s of log 4.2 and log 2.8, respectively. 
One child in the unresolved group had a VL of log 2.4 
while the remaining five children had undetectable VL’s. 
Details of the current ART regimen were available for 
11 of the children in the resolved group and all six of the 
children in the unresolved group. There were no notice-
able distinctions in ART regimens or typical CPE scores 
between the groups, as shown in Table 2.
Discussion
To our knowledge, this is one of the first reports to specifi-
cally describe that increased lower limb muscle tone in chil-
dren with HIVE may resolve over time in some cases. This 
observation naturally led us to consider what factors might 
explain the difference between the resolved and unresolved 
groups and we posed a number of questions as follows.
Is the resolution of increased lower limb muscle tone 
related to age?
There were no significant differences when comparing 
age at PE 1, age at PE 2 or the time period between PE 1 
and PE 2 in the resolved and unresolved groups (Table 1). 
This would suggest that the current observations cannot 
necessarily be attributed to maturational factors.
Is the resolution of increased lower limb muscle tone 
related to the severity of the initial neurological findings?
Those in the resolved group showed less prominent 
increases in muscle tone at PE 1 compared to those in 
the unresolved group. Unfortunately, there was no spe-
cific measure of muscle spasticity with which to firmly 
establish and quantify these differences. Nevertheless, 
the distinction between the groups would suggest that 
the resolution of increased lower limb muscle tone may 
indeed be associated with the severity of the initial neu-
rological findings as distinguished by “spastic diplegia” or 
“increased lower limb muscle tone” at PE 1.
Is the resolution of increased lower limb muscle tone 
related to the duration of ART?
Differences between the resolved and unresolved groups 
did not appear to be related to overall duration of ART 
with no significant differences in the duration on ART 
prior to PE 1 and PE 2 (Fig. 1b, c). Although there was a 
tendency towards a significant difference in duration on 
ART prior to PE 2 between the groups (Fig. 1c, p = 0.08), 
this tendency was towards shorter ART duration in the 
resolved group rather than the unresolved group and 
can be attributed to later ART initiation in the resolved 
group.
Is the resolution of increased lower limb muscle tone 
related to age at the start of ART?
Although there was no significant difference in the age 
of ART initiation between the resolved and unresolved 
groups, all six children in the unresolved group had com-
menced ART by 13 months of age whereas only 4 of the 
13 children in the resolved group had commenced ART 
within this time period.
Unfortunately, start of ART blood test results were not 
available and we were not able to ascertain the health sta-
tus of the children when ART commenced. However, all 
children in the current study would have initiated ART 
Table 1 Overview of participants’ age at initial and follow-up physical examination
PE 1 initial physical examination, PE 2 follow-up physical examination, IQR interquartile range
Resolved group (n = 13) Unresolved group (n = 6) Resolved vs. unresolved
Median (IQR) Median (IQR) p value
Age at PE 1 (years:months) 7:7 (4:0–9:1) 5:9 (3:9–6:9) p = 0.19
Age at PE 2 (years:months) 9:7 (7:3–10:9) 8:6 (7:9–9:7) p = 0.68
Time between PE 1 and PE 2 (years:months) 2:1 (1:2–3:4) 3:7 (1:3–5:3) p = 0.23
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under either the 2004 or 2010 South African National 
ART Guidelines, both of which required children to 
meet certain clinical criteria to be eligible for ART [8, 
9]. Under the 2004 guidelines, infants and children were 
eligible for ART on the basis of (1) recurrent hospitaliza-
tions, (2) a modified World Health Organization Stage II 
or III disease or (3) a CD4 % <20 % [8]. In contrast, the 
2010 guidelines allowed for ART initiation in all HIV-
infected infants irrespective of health status but retained 
criteria of a clinical stage 3 or 4 or CD4 % ≤25 % in order 
to initiate ART in children 1–5 years of age [9].
None of the children in the current study initiated 
ART as an infant under the 2010 guidelines, therefore it 
is likely that all the children commenced ART due to a 
deterioration in health. It follows that all six children in 
the unresolved group may have had significant HIV dis-
ease progression within 13  months of age whereas only 
four of the children in the resolved group appear to have 
met one of the clinical criteria for ART initiation dur-
ing infancy. The remaining nine children in the resolved 
group appear to have only developed significant disease 
progression somewhat later, at 22–106 months of age.
Initiation of ART within the first months of life may 
protect against HIV disease progression and improve 
short-term neurodevelopmental outcomes in HIV-
infected infants who are not yet immune suppressed 
[10, 11]. However, it would appear that the association 
between early ART initiation and improved outcomes 
might not apply to infants whose health has already dete-
riorated prior to ART initiation. In other words, in the 
current study, those who initiated ART in infancy had 
poorer neurological outcomes than those who initiated 
ART somewhat later, most likely due to the former group 
having severe disease progression at an earlier age.
The current observations have a number of limiting 
factors including the small sample size and the absence 
of some key measurements with which to compare the 
resolved and unresolved groups. Missing data include 
immunological and viral load data from the start of ART 
and from PE 1, a means of quantifying muscle spasticity 
Fig. 1 Difference between the resolved- and unresolved groups for: 
a age at the start of anti-retroviral therapy (ART); b time period from 
the start of ART to physical examination (PE) 1; and c time period 
from the start of ART to PE 2. Median value and inter-quartile range 
are indicated
Table 2 Current antiretroviral regimens
NRTI nucleoside reverse transcriptase inhibitor, NNRTI non-nucleoside reverse 
transcriptase inhibitor, PI protease inhibitor, CPE CNS penetration effectiveness, 
AZT zidovudine, 3TC lamivudine, EFV efavirenz, ABC abacavir, LPV/r lopinavir/
ritonavir, d4t stavudine
n NRTI NRTI NNRTI PI CPE score
Resolved group
 1 AZT 3TC LPV/r 9
 5 ABC 3TC LPV/r 8
 3 ABC 3TC EFV 8
 1 d4t 3TC LPV/r 7
 1 d4t 3TC EFV 7
Unresolved group
 1 AZT 3TC EFV 9
 2 ABC 3TC LPV/r 8
 2 d4t 3TC LPV/r 7
 1 d4t 3TC EFV 7
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at PE 1 and PE 2 and more detailed information about 
ART regimens and longitudinal viral suppression. These 
limitations can be attributed to the fact that the current 
report was based on an unanticipated clinical observa-
tions rather than a planned research study. Neverthe-
less, this preliminary discussion could be of immediate 
relevance to healthcare professionals who may wish to 
consider the current findings when assessing the prog-
nosis and orthopedic treatment options for children with 
HIVE who present with increased muscle tone in the 
lower limbs.
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